Temporal‐spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia

Nissa Erickson, Sujit Kumar Mohanty, Pranavkumar Shivakumar, Gregg Sabla, Ranajit Chakraborty, Jorge A. Bezerra – 21 January 2008 – Biliary atresia is a fibro‐inflammatory cholangiopathy that obstructs the extrahepatic bile ducts in young infants. Although the pathogenesis of the disease is undefined, studies in livers from affected children and neonatal mice with experimental biliary atresia have shown increased expression of proapoptosis molecules. Therefore, we hypothesized that apoptosis is a significant mechanism of injury to duct epithelium.

Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders

Nathan A. Johnson, David W. Walton, Toos Sachinwalla, Campbell H. Thompson, Kate Smith, Patricia A. Ruell, Stephen R. Stannard, Jacob George – 21 January 2008 – Nonalcoholic fatty liver is frequently observed in obese individuals, yet the factors that predict its development and progression to liver disease are poorly understood. We proposed that proton magnetic resonance spectroscopy (1H‐MRS) might allow noninvasive assessment of hepatic lipid composition.

The hepatic stem cell niche: Identification by label‐retaining cell assay

Reiichiro Kuwahara, Alexander V. Kofman, Charles S. Landis, E. Scott Swenson, Els Barendswaard, Neil D. Theise – 21 January 2008 – Label retention assays remain the state‐of‐the‐art approach to identify the location of intraorgan epithelial stem cell niches, in situ and in vivo. They are commonly used in organs with rapid cell turnover but have not been applied to the liver, where cell turnover is very slow.

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

Carl J. Baldick, Daniel J. Tenney, Charles E. Mazzucco, Betsy J. Eggers, Ronald E. Rose, Kevin A. Pokornowski, Cheng F. Yu, Richard J. Colonno – 14 January 2008 – Virologic resistance emerging during entecavir (ETV) therapy for hepatitis B virus (HBV) requires three substitutions in the viral reverse transcriptase (RT), signifying a high barrier to resistance.

Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways

Karina Trujillo‐Murillo, Ana Rosa Rincón‐Sánchez, Herminia Martínez‐Rodríguez, Francisco Bosques‐Padilla, Javier Ramos‐Jiménez, Hugo A. Barrera‐Saldaña, Marcos Rojkind, Ana María Rivas‐Estilla – 14 January 2008 – It has been reported that salicylates (sodium salicylate and aspirin) inhibit the replication of flaviviruses, such as Japanese encephalitis virus and dengue virus. Therefore, we considered it important to test whether acetylsalicylic acid (ASA) had anti–hepatitis C virus (HCV) activity.

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

Véronique Loustaud‐Ratti, Sophie Alain, Annick Rousseau, Isabelle Fouchard Hubert, François Ludovic Sauvage, Pierre Marquet, François Denis, Françoise Lunel, Paul Calès, Annie Lefebvre, Anne‐Laure Fauchais, Eric Liozon, Elisabeth Vidal – 14 January 2008 – The impact of ribavirin exposure on sustained virological response (SVR) in patients with chronic hepatitis C is unknown.

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial

Jaime Bosch, Dominique Thabut, Agustín Albillos, Nicolas Carbonell, Julius Spicak, Julien Massard, Gennaro D'Amico, Didier Lebrec, Roberto de Franchis, Søren Fabricius, Yan Cai, Flemming Bendtsen – 14 January 2008 – A beneficial effect of recombinant activated factor VII (rFVIIa) in Child‐Pugh class B and C patients with cirrhosis who have variceal bleeding has been suggested. This randomized controlled trial assessed the efficacy and safety of rFVIIa in patients with advanced cirrhosis and active variceal bleeding.

Suppressor of cytokine signaling 1 protects mice against concanavalin A–induced hepatitis by inhibiting apoptosis

Takehiro Torisu, Mako Nakaya, Satoko Watanabe, Masayuki Hashimoto, Hideyuki Yoshida, Takatoshi Chinen, Ryoko Yoshida, Fuyuki Okamoto, Toshikatsu Hanada, Kumiko Torisu, Giichi Takaesu, Takashi Kobayashi, Hideo Yasukawa, Akihiko Yoshimura – 14 January 2008 – Acute liver failure is associated with significant mortality. However, the underlying pathophysiological mechanism is not yet fully understood. Suppressor of cytokine signaling‐1 (SOCS1), which is a negative‐feedback molecule for cytokine signaling, has been shown to be rapidly induced during liver injury.

TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1–Forkhead box M1 regulation loop

Tae Jun Park, Ji Yeon Kim, S. Paul Oh, So Young Kang, Bong Wan Kim, Hee Jung Wang, Kye Yong Song, Hyoung Chin Kim, In Kyoung Lim – 14 January 2008 – A functional and biochemical interaction of TIS21/BTG2/PC3 with Forkhead box M1 (FoxM1), essential transcription factor for hepatocyte regeneration and a master regulator of mitotic gene expression, was explored.

Retracted: Outcome and immune reconstitution of HBV‐specific immunity in patients with reactivation of occult HBV infection after alemtuzumab‐containing chemotherapy regimen

Chee‐Kin Hui, Winnie W. Cheung, Kar‐Wai Leung, Vincent C. C. Cheng, Bone S. F. Tang, Iris W. S. Li, John M. Luk, Nikki P. Lee, Yok‐Lam Kwong, Wing‐Yan Au, Kwok‐Yung Yuen, George K. Lau, Raymond Liang – 14 January 2008 – Retraction: The following article from HEPATOLOGY, “Outcome and immune reconstitution of HBV‐specific immunity in patients with reactivation of occult HBV infection after alemtuzumab‐containing chemotherapy regiment” by Chee‐Kin Hui, Winnie W. Cheung, Kar‐Wai Leung, Vincent C. C. Cheng, Bone S. F. Tang, Iris W. S. Li, John M. Luk, Nikki P.

Subscribe to